Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 5/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749684 | 0.91 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1KMOCTSATP53 | |
| SCHEMBL3754265 | 0.88 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1CTSAMAPTNPSR1 | |
| SCHEMBL3752748 | 0.81 | CTSA (0.38) | KMOCTSA | |
| SCHEMBL831013 | 0.81 | KMO (0.45) | ALDH1A1L3MBTL1KMOAKR1B10AKR1C4 | |
| SCHEMBL3745600 | 0.81 | KMO (0.47) | ALDH1A1KMOCTSAMAPTNPSR1 | |
| SCHEMBL829626 | 0.81 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1KMOMAPTAKR1B10 | |
| SCHEMBL3757232 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1CTSASCN9A | |
| SCHEMBL3747394 | 0.78 | KMO (0.39) | KMOCTSANPSR1AKR1C3AKR1C2 | |
| SCHEMBL830072 | 0.78 | XDH (0.45) | ALDH1A1L3MBTL1KMOAKR1B10AKR1C4 | |
| SCHEMBL832823 | 0.77 | KMO (0.42) | ALDH1A1L3MBTL1KMOAKR1B10AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | ALDH1A1 1855/4885L3MBTL1 2518/4885KMO 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.